whitepaper
Infographic: Top reasons to select Bethyl bulk antibodies
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
List view / Grid view
Antibodies
whitepaper
ebook: Optimise your high value cell lines
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.
whitepaper
Guide: Eight tips for ensuring a successful ELISA
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
news
Synthetic antibody treats congenital myasthenia in mice
Researchers have designed an antibody that attaches to MuSK, which prevented early lethality of mice with congenital myasthenia.
news
New technique developed for identifying therapeutic nanobodies
Researchers have used a new method for discovering nanobodies to identify potential therapeutics against SARS-CoV-2 infection.
whitepaper
Product hub: Octet® R series systems
Discover the new Octet R series systems, a comprehensive solution for screening and characterising molecular interactions such as protein-protein or protein-drug interactions.
video
Video: Sino Biological: the global leader in recombinant technology
Sino Biological is an international reagent supplier and service provider. The company specialises in recombinant protein production and antibody development.
whitepaper
Brochure: Viral research solutions
Solutions to help you understand viral diseases and translate your research findings into better treatments and vaccines.
news
Dual antibodies effective against SARS-CoV-2 variants in animal study
In mice and hamsters, therapies made from two antibodies were found to be mostly effective against a range of SARS-CoV-2 variants.
article
Better therapeutic antibodies by design
The binding specificity and high binding affinity of therapeutic antibodies makes them an ideal therapy for treating a wide range of human disorders. Advancements in antibody technologies have resulted in huge development success along with a boost in novel and improved treatment strategies. However, specific challenges and considerations are faced…
article
How to mix the best anti-SARS-CoV-2 cocktail
Neutralisation resistance generated by Spike (S) protein mutations in Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) poses a challenge to antibody therapies for COVID-19. Antibody cocktails targeting the S protein receptor binding domain (RBD) are one way to avoid viral neutralisation escape, however only certain antibody combinations are currently effective.…
whitepaper
Catalogue: Resources for COVID-19 and influenza vaccine development
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
whitepaper
ebook: Why you need to digitally transform your R&D organisation
Despite many companies considering digital transformation a top priority, research shows that 70% of digital transformation initiatives fail. In this ebook, we explore why and how the right approach can see your organisation succeed.
article
Drug Target Review Antibodies ebook 2021
Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can take.
news
Two COVID-19 vaccines show safety and strong immunity in infant model
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.